News and blogs

A number of African countries have now approved a vaginal ring that contains the antiretroviral drug dapivirine, which women can use to stop themselves from getting HIV.

From breakthroughs on HIV prevention to a global monkeypox outbreak and the continuing fallout of COVID-19, this has been a year of highs and lows. We look back on five of the most significant moments

More choice for HIV prevention could be on the horizon in Uganda as the government approves a PrEP vaginal ring and is close to approving injectable PrEP

Country will make injectable HIV treatment available from next year

By 2025 1.2 million could be at risk of HIV. Read UNAIDS’ latest data that shows progress on HIV prevention and treatment has stalled, putting millions at risk

A global report on harm reduction for people who use drugs finds services have increased but funding is shrinking

We’re kick-starting open and honest conversations on sexual health and HIV. Are you in?

A pilot offering injectable PrEP to adolescent girls and young women is due to start next year

Dolutegravir is more effective than other antiretroviral drugs at getting HIV back under control if someone’s viral load rises

Growing evidence suggests climate change is affecting HIV epidemics in Africa and elsewhere

Country is the first in Africa and third in the world to approve the use of long-acting cabotegravir to prevent HIV

Latest research shows people with HIV who are vaccinated are unlikely to get seriously ill or die from COVID-19, but those with low CD4 counts are more at risk

Interviews with healthcare workers in Zanzibar reveal a lack of knowledge and equipment to diagnose the disease, risking serious consequences for women’s health, including HIV

HIV criminalisation causes widescale harm, especially to already marginalised groups, global evidence review finds

Research with adolescent girls and young women in South Africa and Zimbabwe finds a link between PrEP adherence and risky behaviour

New strategy outlines how to design messages for groups most at risk of HIV to increase demand for PrEP